Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment

  • Autoimmune Disorder
  • Rheumatoid Arthritis
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Altenburg
  • Amberg
  • Bad Nauheim
  • Berlin
  • Burghausen
  • Dresden
  • Düsseldorf
  • Güstrow
  • Halle (Saale)
  • Hamburg
  • Hannover
  • Heidelberg
  • Magdeburg
  • Mansfeld
  • München
  • Neubrandenburg
  • Offenburg
  • Püttlingen
  • Ratingen
  • Saarbrücken
  • Stuttgart
  • Ulm
Trial Identifier:

NCT03112213 ML30088

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This nationwide, multicenter, single arm, prospective, non-interventional study will evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use in a representative cohort of participant with moderate to severe active RA who have either responded inadequately to, or who were intolerant to previous therapy with one or more synthetic disease modifying anti-rheumatic drug (sDMARD), and for whom the physician has made the individual decision to initiate tocilizumab (subcutaneous [SC] or intravenous [IV]) as first biological disease modifying anti-rheumatic drug (DMARD) therapy according to the summary of product characteristics (SPC).

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT03112213, ML30088 Trial Identifier
      Tocilizumab, NSAIDs Treatments
      Rheumatoid Arthritis Condition
      Official Title

      CONIFER (Characterization of NSAID Intake for Established Rheumatoid Arthritis)

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participants with moderate to severe active RA who have either responded inadequately to, or who were intolerant to, previous therapy with one or more sDMARDs and for whom the physician has made the individual decision to be treated with tocilizumab (SC or IV)
      • Current users of NSAIDs due to RA as assessed by the physician
      Exclusion Criteria
      • Contraindications to treatment with tocilizumab as per SPC
      • Prior therapy with tocilizumab

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Rheumatoid Arthritis

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now